Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 8/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.44 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488044 | 0.92 | PIK3C2B (0.51) | MCL1PLA2G2APIK3C2BDCTPP1 | |
| SCHEMBL6489813 | 0.90 | MCL1 (0.43) | MCL1PLA2G2APPARGFFAR1FFAR4 | |
| SCHEMBL6489154 | 0.90 | ALDH1A1 (0.47) | MCL1PLA2G2APPARGDCTPP1 | |
| SCHEMBL6490634 | 0.89 | MCL1 (0.46) | MCL1PLA2G2APPARGFFAR4 | |
| SCHEMBL6501595 | 0.89 | MCL1 (0.46) | MCL1PLA2G2AFFAR1FFAR4DCTPP1 | |
| SCHEMBL6502699 | 0.88 | MCL1 (0.46) | MCL1PLA2G2AFFAR4DCTPP1 | |
| SCHEMBL6489649 | 0.87 | MCL1 (0.44) | MCL1PLA2G2APIK3C2BPPARGFFAR4 | |
| SCHEMBL6501386 | 0.87 | MCL1 (0.48) | MCL1PLA2G2AFFAR1FFAR4DCTPP1 | |
| SCHEMBL6488344 | 0.86 | MCL1 (0.47) | MCL1PLA2G2APPARGFFAR1FFAR4 | |
| SCHEMBL6501119 | 0.86 | MCL1 (0.43) | MCL1PLA2G2AFFAR4DCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | MCL1 806/4885PLA2G2A 4801/4885PIK3C2B 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.